EE200000147A - April - uus kasvuefekte omav valk - Google Patents

April - uus kasvuefekte omav valk

Info

Publication number
EE200000147A
EE200000147A EEP200000147A EEP200000147A EE200000147A EE 200000147 A EE200000147 A EE 200000147A EE P200000147 A EEP200000147 A EE P200000147A EE P200000147 A EEP200000147 A EE P200000147A EE 200000147 A EE200000147 A EE 200000147A
Authority
EE
Estonia
Prior art keywords
april
new growth
growth protein
protein
new
Prior art date
Application number
EEP200000147A
Other languages
English (en)
Inventor
Tschopp Jurg
Original Assignee
Biogen, Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Incorporated filed Critical Biogen, Incorporated
Publication of EE200000147A publication Critical patent/EE200000147A/et

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/525Tumour necrosis factor [TNF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EEP200000147A 1997-09-12 1998-09-11 April - uus kasvuefekte omav valk EE200000147A (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5878697P 1997-09-12 1997-09-12
US7938498P 1998-03-26 1998-03-26
PCT/US1998/019191 WO1999012965A2 (en) 1997-09-12 1998-09-11 April- a novel protein with growth effects

Publications (1)

Publication Number Publication Date
EE200000147A true EE200000147A (et) 2001-02-15

Family

ID=26738027

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000147A EE200000147A (et) 1997-09-12 1998-09-11 April - uus kasvuefekte omav valk

Country Status (20)

Country Link
US (3) US20030138884A1 (et)
EP (1) EP1027431A2 (et)
JP (1) JP2001515712A (et)
KR (1) KR100618492B1 (et)
CN (1) CN1195849C (et)
AU (1) AU759717B2 (et)
BR (1) BR9812634A (et)
CA (1) CA2303615A1 (et)
CZ (1) CZ294615B6 (et)
EA (1) EA005411B1 (et)
EE (1) EE200000147A (et)
HU (1) HUP0004611A3 (et)
IL (1) IL134537A0 (et)
IS (1) IS5378A (et)
NO (1) NO20001242L (et)
NZ (1) NZ503850A (et)
PL (1) PL339463A1 (et)
SK (1) SK3542000A3 (et)
TR (1) TR200000669T2 (et)
WO (1) WO1999012965A2 (et)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217788B2 (en) 1996-03-14 2007-05-15 Human Genome Sciences, Inc. Human tumor necrosis factor delta polypeptides
US6541224B2 (en) 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
WO1999026976A1 (en) * 1997-11-26 1999-06-03 Eli Lilly And Company Tnf ligand family gene
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
EP2319527A3 (en) 1999-01-25 2011-10-12 Biogen Idec MA Inc. BAFF, inhibitors thereof and their use in the modulation of the B-cell response
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
GEP20053685B (en) * 1999-08-17 2005-12-12 Biogen Inc BAFF Receptor (BCMA), an Immunoregulatory Agent
UA74798C2 (uk) * 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
WO2001025256A2 (en) * 1999-10-06 2001-04-12 University Of Utah Research Foundation Trdl-1-gamma, a novel tumor necrosis-like ligand
AU3495301A (en) 2000-02-11 2001-08-20 Biogen Inc Heterologous polypeptide of the tnf family
AU2006201471B2 (en) * 2000-02-16 2009-07-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of TNF-related molecules
CA2396793A1 (en) * 2000-02-16 2001-08-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
MXPA02011130A (es) * 2000-05-12 2003-03-10 Amgen Inc Metodos y composiciones de materia que se refieren a april/g70, bcma, blys/agp-3, y taci.
EP2431054A3 (en) * 2000-06-15 2013-03-06 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
GB2370273A (en) * 2000-12-20 2002-06-26 Viaxxel Biotech Gmbh Compounds that affect CD83 expression
US7189820B2 (en) 2001-05-24 2007-03-13 Human Genome Sciences, Inc. Antibodies against tumor necrosis factor delta (APRIL)
EA007275B1 (ru) 2001-05-24 2006-08-25 Займодженетикс, Инк. Слитые белки taci-иммуноглобулина
EP1576088A4 (en) 2002-01-04 2006-09-06 Xencor Inc DOMINANT NEGATIVE PROTEINS AND METHOD THEREFOR
US7381792B2 (en) 2002-01-04 2008-06-03 Xencor, Inc. Variants of RANKL protein
US7553930B2 (en) 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
WO2004089982A2 (en) * 2003-01-06 2004-10-21 Xencor April variants and methods thereof
AU2004233164B2 (en) 2003-03-28 2009-10-08 Biogen Ma Inc. Truncated BAFF receptors
CA2554526A1 (en) * 2004-01-29 2005-08-18 Genentech, Inc. Variants of the extracellular domain of bcma and uses thereof
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
WO2005113598A2 (en) * 2004-05-21 2005-12-01 Xencor, Inc. Tnf super family members with altered immunogenicity
JP2008525002A (ja) 2004-12-23 2008-07-17 ラボラトワール セローノ ソシエテ アノニム Bcmaポリペプチド及びその使用
CN101262876A (zh) 2005-08-09 2008-09-10 酶遗传学股份有限公司 用taci-ig融合分子治疗b细胞恶性肿瘤的方法
US8808696B2 (en) 2005-08-09 2014-08-19 Ares Trading S.A. Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules
DE602006020467D1 (de) 2005-09-26 2011-04-14 Enzo Life Sciences Els Ag Antikörper gegen april als biomarker zur frühen prognose in lymphompatienten
AU2006344395B2 (en) 2005-10-13 2013-05-02 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive diseases
WO2007062090A2 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
EA015342B1 (ru) 2006-05-15 2011-06-30 Арес Трейдинг С.А. Способы лечения аутоиммунных заболеваний с использованием слитой молекулы taci-ig
EP2403528B1 (en) 2009-03-02 2016-04-20 Aduro Biotech Holdings, Europe B.V. Antibodies against a proliferating inducing ligand (april)
US8981057B2 (en) * 2010-03-05 2015-03-17 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam B-cell stimulating fusion proteins of an antigen with BAFF or APRIL
WO2011109280A1 (en) 2010-03-05 2011-09-09 Lerner Research Institute Methods and compositions to treat immune-mediated disorders
NL2011406C2 (en) 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
KR102407354B1 (ko) * 2013-09-23 2022-06-10 리제너론 파마슈티칼스 인코포레이티드 인간화된 신호-조절 단백질 유전자를 가지는 비-인간 동물
GB201317929D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
SG10201811701YA (en) * 2013-11-19 2019-01-30 Regeneron Pharma Non-human animals having a humanized a proliferation-inducing ligand gene
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
EP3380522B1 (en) 2015-11-25 2023-11-08 Visterra, Inc. Antibody molecules to april and uses thereof
JP2023548866A (ja) 2020-10-29 2023-11-21 インダストリアル ポリマーズ アンド ケミカルズ, インコーポレイテッド 病原体監視及び不活性化のエアフィルター
AU2022327178A1 (en) 2021-08-11 2024-03-28 Akso Biopharmaceutical, Inc. METHODS OF REDUCING PRODUCTION OF IgA, IgM AND/OR IgG USING sBCMA VARIANTS AND FC FUSION PROTEINS THEREOF

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5176996A (en) * 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) * 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) * 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
AU6166396A (en) * 1995-06-07 1996-12-30 Biogen, Inc. Complexes of modified lymphotoxins as pharmaceutical prepara tions
JP2001501453A (ja) * 1996-03-14 2001-02-06 ヒューマン ジノーム サイエンシーズ,インコーポレイテッド ヒト腫瘍壊死因子δおよびε
US6509170B1 (en) * 1996-03-14 2003-01-21 Human Genome Sciences, Inc. Polynucleotides encoding human tumor necrosis factor delta
US6171787B1 (en) * 1997-06-26 2001-01-09 Abbott Laboratories Member of the TNF family useful for treatment and diagnosis of disease

Also Published As

Publication number Publication date
KR100618492B1 (ko) 2006-08-31
IL134537A0 (en) 2001-04-30
PL339463A1 (en) 2000-12-18
CA2303615A1 (en) 1999-03-18
EA005411B1 (ru) 2005-02-24
EA200000310A1 (ru) 2000-10-30
US20050112596A1 (en) 2005-05-26
KR20010023893A (ko) 2001-03-26
CZ294615B6 (cs) 2005-02-16
HUP0004611A2 (hu) 2001-04-28
NO20001242L (no) 2000-05-11
NO20001242D0 (no) 2000-03-09
HUP0004611A3 (en) 2002-04-29
US20030138884A1 (en) 2003-07-24
US20060084148A1 (en) 2006-04-20
CZ2000869A3 (cs) 2000-09-13
WO1999012965A2 (en) 1999-03-18
WO1999012965A3 (en) 1999-06-03
IS5378A (is) 2000-02-18
SK3542000A3 (en) 2000-08-14
AU9316298A (en) 1999-03-29
AU759717B2 (en) 2003-04-17
CN1195849C (zh) 2005-04-06
JP2001515712A (ja) 2001-09-25
EP1027431A2 (en) 2000-08-16
CN1270632A (zh) 2000-10-18
NZ503850A (en) 2002-12-20
BR9812634A (pt) 2000-08-22
TR200000669T2 (tr) 2000-08-21

Similar Documents

Publication Publication Date Title
EE200000147A (et) April - uus kasvuefekte omav valk
NO983364D0 (no) Konsensusproteiner
DE59806239D1 (de) Mähdrescher
NO2010022I1 (no) Denosumab
DE69839603D1 (de) Zierenden proteins
DE69820156D1 (de) VErbessertes monofilament
DE69824232D1 (de) Gefriergerät
DE59706733D1 (de) Erntemaschine
DK0832553T3 (da) Mejetærsker
DE69802241D1 (de) Mähmaschine
DE59705517D1 (de) Mähdrescher
FR2747908B1 (fr) Suture irrigatrice
ID22391A (id) Alat pendingin
ATE295417T1 (de) Angiostatin-bindendes protein
DE59808209D1 (de) Mähdrescher
TR199701666A3 (tr) Sismanliga karsi proteinler
DE69704693D1 (de) Mähdrescher
DE59809449D1 (de) Mähdrescher
DE69636232D1 (de) Wachstumsfaktor htter36
ATA126198A (de) Mähwerk
DE69801101D1 (de) Kraftzange
DK1088069T3 (da) Angiostatin-bindende protein
SE9802189D0 (sv) New Proteins
KR970056464U (ko) 개량 낚시
FI3923U1 (fi) Karsimiskone

Legal Events

Date Code Title Description
HC1A Change of owner name